Search research articles
Contact Us
Filters
Showing results (31-40 of 102) with videos related to
Page
of 11
Sort By:
Journal of Psychiatric Practice
|
January 9, 2020
Repetitive Transcranial Magnetic Stimulation in the Treatment of Bipolar Depression: Experience From a Clinical Setting
Angela L Phillips, Robert L Burr, David L Dunner
Journal of Affective Disorders
|
August 27, 2018
rTMS effects in patients with co-morbid somatic pain and depressive mood disorders
Angela L Phillips, Robert L Burr, David L Dunner
Bipolar Disorders
|
March 12, 2008
Rapid cycling bipolar disorder--diagnostic concepts
Michael Bauer, Serge Beaulieu, David L Dunner, et al.
Clinical Therapeutics
|
March 2, 2006
Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials
David L Dunner, Alan Lipschitz, Cornelius D Pitts, et al.
Journal of Medical Economics
|
September 8, 2012
Medicare patient experience with vagus nerve stimulation for treatment-resistant depression
Rachel L Feldman, David L Dunner, James S Muller, et al.
Convulsive Therapy
|
January 1, 1987
Treatment Options in Severe Psychotic Depression
Arifulla Khan, Seth Cohen, Michelle Stowell, et al.
Depression and Anxiety
|
September 10, 2003
Duloxetine in treatment of anxiety symptoms associated with depression
David L Dunner, David J Goldstein, Craig Mallinckrodt, et al.
Journal of Affective Disorders
|
April 2, 2008
Psychotic symptoms in patients with bipolar mania
Carla M Canuso, Cynthia A Bossie, Young Zhu, et al.
The Journal of Clinical Psychiatry
|
August 10, 2007
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study
David L Dunner, Jay D Amsterdam, Richard C Shelton, et al.
Current Therapeutic Research, Clinical and Experimental
|
March 29, 2014
Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses
David L Dunner, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 102) with videos related to
Sort By:
Page
of 11
Journal of Psychiatric Practice
|
January 9, 2020
Repetitive Transcranial Magnetic Stimulation in the Treatment of Bipolar Depression: Experience From a Clinical Setting
Angela L Phillips, Robert L Burr, David L Dunner
Journal of Affective Disorders
|
August 27, 2018
rTMS effects in patients with co-morbid somatic pain and depressive mood disorders
Angela L Phillips, Robert L Burr, David L Dunner
Bipolar Disorders
|
March 12, 2008
Rapid cycling bipolar disorder--diagnostic concepts
Michael Bauer, Serge Beaulieu, David L Dunner, et al.
Clinical Therapeutics
|
March 2, 2006
Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials
David L Dunner, Alan Lipschitz, Cornelius D Pitts, et al.
Journal of Medical Economics
|
September 8, 2012
Medicare patient experience with vagus nerve stimulation for treatment-resistant depression
Rachel L Feldman, David L Dunner, James S Muller, et al.
Convulsive Therapy
|
January 1, 1987
Treatment Options in Severe Psychotic Depression
Arifulla Khan, Seth Cohen, Michelle Stowell, et al.
Depression and Anxiety
|
September 10, 2003
Duloxetine in treatment of anxiety symptoms associated with depression
David L Dunner, David J Goldstein, Craig Mallinckrodt, et al.
Journal of Affective Disorders
|
April 2, 2008
Psychotic symptoms in patients with bipolar mania
Carla M Canuso, Cynthia A Bossie, Young Zhu, et al.
The Journal of Clinical Psychiatry
|
August 10, 2007
Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study
David L Dunner, Jay D Amsterdam, Richard C Shelton, et al.
Current Therapeutic Research, Clinical and Experimental
|
March 29, 2014
Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses
David L Dunner, Madelaine M Wohlreich, Craig H Mallinckrodt, et al.
Page
of 11